Altimmune Interest Expense | ALT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Altimmune

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
-190 K	48 K	35 K	8 K	5 K	9.42 K	2.24 K	297 K	162 K	38.5 K	54.6 K	210 K	367 K	325 K	54.6 K	5.94 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.94 M	-190 K	460 K

Quarterly Interest Expense Altimmune

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-92 K	-152 K	-	-86 K	-92 K	15 K	-	18 K	-76 K	-12 K	-	14 K	113 K	2 K	-	64 K	65 K	62 K	-	33 K	22 K	12 K	-	2.28 K	3.31 K	1.88 K	-	756	748	740	-	167 K	1.92 K	870	-	2.34 K	97.2 K	60.6 K	-	9.41 K	9.62 K	1.05 K	-	9.89 K	13.3 K	25.3 K	-	46.9 K	56.6 K	69.9 K	-	89.8 K	100 K	99.8 K	-	113 K	111 K	3.03 K	-	9.93 K	15.2 K	15.4 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
167 K	-152 K	22.3 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	197 K	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
Codexis CDXS	-4.81 M	$ 1.42	0.33 %	$ 124 M	USA
Synthetic Biologics SYN	95 K	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	293 K	-	-	$ 2.02 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Qilian International Holding Group Limited QLI	555 K	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	263 K	-	1.35 %	$ 17.8 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Cue Biopharma CUE	100 K	$ 27.67	2.63 %	$ 2.62 B	USA
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Hepion Pharmaceuticals HEPA	9.46 K	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	-12 K	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Editas Medicine EDIT	-2.19 M	$ 3.08	0.33 %	$ 273 M	USA
Ardelyx ARDX	4.95 M	$ 3.71	1.06 %	$ 894 M	USA
EyePoint Pharmaceuticals EYPT	11.8 M	$ 4.57	0.21 %	$ 335 K	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.66	0.04 %	$ 3.01 B	USA
Assembly Biosciences ASMB	117 K	$ 36.13	4.38 %	$ 405 M	USA
Fate Therapeutics FATE	11.4 M	$ 2.42	0.61 %	$ 287 M	USA
AnPac Bio-Medical Science Co., Ltd. ANPC	236 K	-	-1.58 %	$ 28.1 M	China
Adial Pharmaceuticals ADIL	165 K	$ 6.66	5.38 %	$ 4.45 M	USA
Fortress Biotech FBIO	17.6 M	$ 2.71	0.04 %	$ 75.6 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Axsome Therapeutics AXSM	-15.9 M	$ 208.35	0.16 %	$ 10.4 B	USA
GlycoMimetics GLYC	651 K	-	9357.83 %	$ 1.01 B	USA
AnaptysBio ANAB	5.43 M	$ 57.46	2.9 %	$ 1.65 B	USA
AVROBIO AVRO	-119 K	-	1083.1 %	$ 745 M	USA
BioMarin Pharmaceutical BMRN	17.3 M	$ 66.43	0.04 %	$ 12.7 B	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands